research Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
Search
for
Sort by
Research
180-210 / 1000+ results 
research Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.
research Rethinking the classification of alopecia areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research Alopecia areata and vitamin D: Is there any association?
People with alopecia areata often have lower vitamin D levels than healthy people.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research The efficacy and safety of BM-PHA for the correction of nasolabial folds: a multicenter, randomized, double-blind, split-face clinical trial
BM-PHA is as effective and safe as Restylane Perlane for improving nasolabial folds with minor side effects.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8‐methoxypsoralen application
This therapy effectively treats resistant alopecia areata with minimal side effects.
research A clinical study on alopecia areata
Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
research Tratamento adjuvante com minoxidil oral para tratamento de alopecia areata refratária a inibidores de JAK
Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Efficacy of Oral Apremilast in The Treatment of Alopecia Areata, at The Tertiary Care Hospital, Karachi
Oral Apremilast effectively treats alopecia areata in most patients.
research The efficacy and safety of tofacitinib in patients with alopecia totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
research In reply
Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
research Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
research Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients
Allergen desensitization reduces hair loss severity in dust-mite allergic alopecia areata patients.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
research Objective outcome measures: Collecting meaningful data on alopecia areata
The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
research Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.